Yangtze River Pharmaceutical Group Co., Ltd.

Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

Zf Asia Pacific Automotive Safety Systems (shanghai) Co., Ltd.

Taotao Jiang

Xing Liu

Zheng Wang

Jiong Lan

Qiang Xu

Hui Yang

Yuanyi Cheng

Hai Wang

Daofei Li

Zhaoling Dan

Jibiao Wang

An occupant protection method and system, and a computer-readable medium, where the method includes: S: collecting external environment information of a vehicle; S: determining, based on the environment information, whether there is an obstacle within a monitoring area, and if yes, proceeding to step S; or if no, returning to step S; S: predicting a movement trajectory of the obstacle; S: calculating a probability of collision between the vehicle and the obstacle based on vehicle body data and motion information of the vehicle, and the movement trajectory of the obstacle; S: determining whether the probability of collision is greater than a collision threshold, and if yes, proceeding to step S; or if no, returning to step S; S: partially inflating a seat cushion airbag of the vehicle to adjust a sitting posture of an occupant; S: determining whether a collision is detected, and if yes, proceeding to step S; or if no, returning to step S; and S: fully inflating the seat cushion airbag.

Occupant protection method and system, and computer readable medium

The present disclosure discloses sodium ion channel inhibitors, pharmaceutically acceptable salts and polymorphs thereof, and uses thereof. Specifically, the present disclosure discloses a polymorph of a compound of formula (X) and a preparation method thereof. The preparation method of the present disclosure is simple in operation and suitable for industrialization. The polymorph prepared by the preparation method has advantages of good stability, low hygroscopicity and high water solubility. 

Sodium ion channel inhibitors and pharmaceutically acceptable salts and polymorphs thereof and uses thereof

Provided is an EGFR inhibitor and a pharmaceutically acceptable salt and a polymorph thereof, and a use thereof. In particular, provided is a polymorph, a pharmaceutically acceptable salt or a prodrug of N-(2-(4-(dimethylamino)piperid-1-yl)-5-(5-fluoro-4-(1-methyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino)-4-methoxy phenyl) acrylamide. In addition, also provided is a pharmaceutical composition containing the inhibitor and a use thereof.

EGFR inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof

The present invention relates to a PI3K inhibitor, and a pharmaceutically acceptable salt, polycrystalline form, and application thereof. The invention specifically provides a polycrystalline form of 4-chloro-5-(6-(1-(methylsulfonyl)cyclopropyl)-2-morpholinopyrimidin-4-yl)pyridin-2-amine, a pharmaceutically acceptable salt thereof, or a polycrystalline form of the salt. The invention further discloses a pharmaceutical composition comprising the inhibitor and an application of the pharmaceutical composition.

PI3K inhibitor, and pharmaceutically acceptable salt, polycrystalline form, and application thereof

Growing community of inventors

Shanghai, China

Taotao Jiang